NCT02368119View on ClinicalTrials.gov

Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 27, 2016

Study Completion Date

September 27, 2016

Conditions
Ebola Virus DiseaseHemorrhagic Fever
Interventions
BIOLOGICAL

VRC-EBOADC069-00-vp

IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)

BIOLOGICAL

VRC-EBOADC069-00-vp

IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)

BIOLOGICAL

MVA-EbolaZ

IM injection of MVA-EbolaZ vaccine

OTHER

Placebo

IM injection injection of Phosphate Buffered Saline

Trial Locations (1)

Unknown

Centre pour le Developpement des Vaccins - Mali, Bamako

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT02368119 - Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO) | Biotech Hunter | Biotech Hunter